# Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

> **NCT06536400** · PHASE1 · RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 316 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** HSK42360

## Key facts

- **NCT ID:** NCT06536400
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-25
- **Primary completion:** 2026-08-30
- **Final completion:** 2027-07-07
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536400, "Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06536400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*